Ann: SIRFLOX ASCO Abstract Released, page-76

In the SRX Investor Lunch and Learn presentation from Dec2014 (page 70), SRX stated that at ASCO they expect to see detailed data from the primary AND secondary end points of the trial.

Secondary end point data expected include:

OVERALL Survival (so there may in fact be some OS data presented in less than 2 weeks)
PFS in the liver
Tumour response rate
Hepatic and extra- hepatic response rate
Quality of life
Toxicity and safety
Liver resection rate